思瑞浦(688536.SH):擬與關聯方等共同向士模微增資
格隆匯 2 月 22日丨思瑞浦(688536.SH)公佈,公司擬與關聯方義烏華芯遠景創業投資中心(有限合夥)、無限啟航創業投資(天津)合夥企業(有限合夥)共同向北京士模微電子有限責任公司(“士模微”或“標的公司”)增資,其中公司以自有資金投資750萬元人民幣,佔此次增資後標的公司註冊資本的5%。
截至目前,士模微成立尚不足一年。標的公司尚處於初創階段,其後續發展受到政策環境、技術水平、市場競爭等多重因素的影響,具有一定的不確定性,存在業務發展不及預期及短期內無法盈利的風險。公司此次投資存在無法實現預期協同效應及投資收益的風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.